Actionable news
0
All posts from Actionable news
Actionable news in KITE: KITE PHARMA Inc,

Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD

SANTA MONICA, Calif.--(BUSINESS WIRE)--

Kite Pharma, Inc., (KITE), a leading cell therapy company, today highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD. The study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), showed outcomes in patients with refractory aggressive NHL subtypes including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) or primary mediastinal B-cell lymphoma (PMBCL) following treatment with currently available therapies:

  • Objective response rate of 26 percent
  • Complete response rate of 7 percent
  • Median overall survival of 6.3 months

These findings highlight the unmet medical need and provide an important benchmark for studies that address this refractory patient population.

“SCHOLAR-1 demonstrates the uniformly poor treatment outcomes for patients with aggressive non-Hodgkin lymphoma and emphasizes the need for breakthrough therapies for these refractory patients,” said Christian Gisselbrecht, MD, Professor of Hematology, Saint Louis Hospital at Diderot University Paris 7, and corresponding author of the study. “Although 60 to 70 percent of non-Hodgkin lymphoma patients survive five years after rituximab-based chemotherapy and autologous stem cell transplant, nearly half of them either do not respond or relapse shortly after transplant. SCHOLAR-1 provides a rigorous measure of outcomes for these patients who do not benefit from...


More